ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Altimmune, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.23+0.03 (+1.36%)
Close on Oct 19, 2026
- Market cap
- $413.54M
- P/E (TTM)
- –
- Dividend yield
- –
Altimmune, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 18 | Q3 18 | Q2 18 | Q4 17 | Q3 17 | Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Grant [Member] | $2.58M | $2.63M | $2.41M | $2.80M | $4.57M | $3.03M | 99.8% | -7.9% |
| License Revenue [Member] | $4.95K | $4.95K | $4.95K | $4.94K | $26.69K | $4.94K | 0.2% | +0.2% |
By region
From the segment and revenue-disaggregation notes of Altimmune's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.